- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 271/07 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
Patent holdings for IPC class C07D 271/07
Total number of patents in this class: 165
10-year publication summary
|
13
|
22
|
15
|
10
|
15
|
10
|
6
|
15
|
10
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 460 |
6 |
| Farmington Pharma Development | 7 |
5 |
| Oryzon Genomics S.A. | 106 |
5 |
| Novassay S.A. | 10 |
4 |
| Romark Laboratories L.C. | 52 |
4 |
| Janssen Pharmaceutica N.V. | 3396 |
3 |
| Bayer Intellectual Property GmbH | 2509 |
3 |
| Bayer Cropscience AG | 2051 |
3 |
| Bayer Pharma AG | 1061 |
3 |
| King Faisal University | 908 |
3 |
| The Board of Regents of the University of Texas System | 2204 |
3 |
| Calico Life Sciences LLC | 96 |
3 |
| Merck Sharp & Dohme LLC | 3751 |
3 |
| Bristol-myers Squibb Company | 4879 |
2 |
| BASF SE | 20892 |
2 |
| Boehringer Ingelheim International GmbH | 4697 |
2 |
| Abbvie Inc. | 1800 |
2 |
| Takeda Pharmaceutical Company Limited | 2712 |
2 |
| Vertex Pharmaceuticals Incorporated | 1595 |
2 |
| Northwestern University | 3374 |
2 |
| Other owners | 103 |